Does it suggest that the regulators and/or CHM want to assess whether its the delivery method (of bypassing the blood-brain barrier) that is resulting in our impressive data? It's almost like a control arm has been added to the trial design.... to compare CLTX to chemo. I dare say its something to do with our TGA regulations.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)